Introduction

Heart failure (HF) is a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood (Yancy et al. 2013). Pathophysiology of heart failure involves the activation of a number of neurohormonal systems in response to any form of cardiac injury.

HF may be associated with a wide spectrum of LV functional abnormalities, which may range from patients with normal LV size and preserved ejection fraction (EF) to those with severe dilatation and/or markedly reduced EF. In most patients, abnormalities of systolic and diastolic dysfunction coexist, irrespective of EF.

EF is considered important in classification of patients with HF because of differing patient demographics, comorbid conditions, prognosis, and response to therapies (Drazner et al. 2001).

In chronic HF predominantly the sympathetic nervous system and the renin-angiotensin aldosterone system
(RAAS) systems become upregulated. Specific agents that target the RAAS are angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists (Miller, 2007).

Clinical trials have demonstrated mortality and morbidity benefits of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure. These studies have used either eplerenone or spironolactone as the MRA. (Zannad et al., 2004, Juurlink et al., 2004).

Spironolactone (or its metabolite, potassium canrenoate) and eplerenone are the currently licensed MRAs for clinical use. However, studies have reported that compared to placebo, eplerenone was associated with significant improvement in systolic function (Marrs, et al., 2018).

Eplerenone is a selective aldosterone antagonist and has been shown to have fewer incidence of hormonal side effects than spironolactone. Evidence from trials shows that eplerenone improves survival and reduces cardiovascular mortality and hospitalization, compared with standard treatment alone. Eplerenone was found to be more effective but also more costly than standard treatment (Nadin, 2005).

Previously spironolactone and eplerenone was studied separately with placebo arm. Upon journal review no head to head trial between these two drugs is found regarding improvement of systolic function, tolerability and safety. Aim of our study was to compare the left ventricular systolic function in chronic heart failure patient treated with spironolactone and eplerenone in our setting.

Methods

Study design and patients

This randomized single blind clinical trial was conducted at the University Cardiac Center, Bangabandhu Sheikh Mujib Medical University, Dhaka. The centre is currently being ranked as one of the top hospitals in Bangladesh. Total duration was 1 year from July, 2017 to June, 2018. We studied 224 adult patients (age > 15 years) of heart failure with reduced EF. All patients had New York Heart Association class III or IV symptoms for ≥3 months and an LV ejection fraction < 40% by echocardiography. Patients were excluded if serum creatinine was > 2.5 mg/dl on previous medical records, serum potassium level > 5 mmol/L on previous medical records, systolic blood pressure < 85 mm Hg or prior history of aldosterone antagonist hypersensitivity. The protocol was approved by the Institutional Review Board (IRB). Written informed consent was obtained from all study patients after careful explanation of the study procedures.

Study Procedure

All patients with chronic heart failure were enrolled purposively following the inclusion and exclusion criteria. Detailed history, physical examination and an echocardiogram were done on admission and outpatient consultation. After enrollment the study subject were divided into 2 arms randomly by using online graph pad software: spironolactone (arm I) and eplerenone (arm II).

In addition to study drug, standard treatments for CHF according to the ACC/AHA HF Guideline 2013 were permitted. Up and down titration of the index drug was done according to patients need. Up and down titration of drug dose was done according to patients need. At the end of the 1st month of treatment, patients were followed up using serum creatinine and serum electrolytes and dose adjustment was done accordingly. At the end of the 6th month LV systolic function of all cases was compared with their baseline echocardiographic data. Detail clinical evaluation for improvement of symptoms including adverse effects of medications and echocardiographic assessment of LV systolic function of all the cases were performed at baseline and after 6 months of treatment with spironolactone or eplerenone arm. Echocardiographic assessment was done by using 2D and M-mode echocardiography. The LV ejection fraction (LVEF) was calculated using a standard method (modified Simpson method) in Vivid E9 (GE Healthcare) echo machine with 3.5 MHz transducer. During echocardiography the following parameters were assessed: left ventricular end diastolic dimension (LVIDd), left ventricular end systolic dimension (LVIDs), left ventricular end diastolic volume and left ventricular end systolic volume. Two independent, blinded observers reviewed these echocardiograms. After completion of the data collection, comparison was done between two (baseline and after 6 months of treatment) echocardiographic finding and inference was drawn.

Statistical analysis

The primary end point of the study was LV study: Left ventricular end diastolic dimension (LVIDd), Left ventricular end systolic dimension (LVIDs), Left ventricular end diastolic volume (EDV), Left ventricular end systolic volume (ESV), The LV ejection fraction (LVEF). Secondary efficacy end point variable was the effect on blood pressure. Keeping the research topic in concern, a preset easily understandable data sheet was used for data collection. After collection of all information, these data were checked, verified for consistency and edited for finalized result. Data cleaning validation and analysis was...
performed using the software SPSS (Statistical Package for Social Science) version 23.0. Descriptive statistics were used to summarize data using means, standard deviation and median for continuous variables. Categorical data were summarized by calculating percentages which were presented as frequency tables and charts. Symmetrical continuous data by t-test and asymmetrical data by Mann-Whitney U Test was compared. Significance was defined as P value less than 0.05.

Results
A total 224 patients were selected for study. Each patient was allocated into one of the two arms, and continued receiving treatment with either spironolactone (ARM-I) or eplerenone (ARM-II). Each patient was evaluated clinically and echocardiographically at the beginning of treatment (baseline) and at the end of 6th month. The number of patients who lost to follow-up was 7 in spironolactone arm and 10 in eplerenone arm.

As shown in Table 1, there were no significant differences between the two arms in terms of socio-demographic data including age, gender, body weight, hypertension, diabetes mellitus, hyperlipidemia and smoking at baseline. With regard to cardiac medications, administration of diuretics, angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), beta blockers, nitrates, statins and antiplatelet was similar in both arms.

Left ventricular volume, dimension and function
Left ventricular volumes and function data are presented in Table 2. After 6 months of treatment, significant improvement of left ventricular ejection fraction was observed in eplerenone treated arm (38.3 ± 4.6 in arm I versus 40.3 ± 6.5 in arm II; P < 0.05). Ejection fraction (EF) changes were 6.2% in eplerenone arm and 4.1% in spironolactone arm.

A significant reduction in left ventricular end-systolic volume (7.0±1.9ml in arm I versus 18.3±6.3ml in arm II; P < 0.05) and left ventricular systolic diameter (2.4±0.9mm in arm I versus 6.8±0.1 mm in arm II; P<0.05) occurred after 6 months of treatment. But no significant differences were observed in reduction of left ventricular end-diastolic volume (3.1±0.3ml versus 14.2±1.8ml; P=0.101) and left ventricular diastolic diameter (1.2±0.8 versus 1.7±0.1; P=0.081) between arms.

Table-I
Baseline characteristics of study patients

|                          | Spironolactone (n=112) | Eplerenone (n=112) | P-value |
|--------------------------|------------------------|--------------------|---------|
| Age (mean±SD)            | 53.1±7.9               | 52.9±8.2           | 0.219   |
| Sex                      |                         |                    |         |
| Male (%)                 | 76(67.8%)              | 72(64.2%)          | 0.283   |
| Female (%)               | 49 (34.1%)             | 40(35.7%)          |         |
| Blood Pressure (mean±SD) |                         |                    |         |
| Systolic                 | 109.8±11.1             | 108.6±12.9         | 0.098   |
| Diastolic                | 73.1±7.8               | 72.3±8.5           | 1.008   |
| Medication               |                         |                    |         |
| Diuretics                | 112(100.0%)            | 144(100.0%)        | 0.119   |
| B-blocker                | 54 (48.2%)             | 48(42.8%)          | 0.149   |
| ACEI                     | 63 (56.2%)             | 68 (60.7%)         | 0.207   |
| ARB                      | 38 (33.9%)             | 42 (37.5%)         | 0.296   |
| Nitrate                  | 21 (18.7%)             | 18 (16%)           | 0.116   |
| Statin                   | 7 (69.6%)              | 73 (65.1%)         | 0.223   |
| Antiplatelet             | 85(75.8%)              | 82(73.2%)          |         |
Effects on blood pressure
Assessment of blood pressure after six months of treatment shows, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were improved in both group but difference between two groups were statistically non-significant (p>0.05) Table 3.

Adverse effect of medication
Although no significant differences of adverse event observed between arms, arm I or patients receiving spironolactone had experienced more adverse profile than eplerenone arm. Adverse profile of medication shows that, in arms I patients, gynecomastia occurred in 10.4% of patients, dizziness in 11.4%, mastalgia in 5.7% and menstrual disturbance in 3.8% patients. In arms II patient’s dizziness in 3.9% of patients and menstrual disturbance in 0.9% patients. None of patient observed developed mastalgia, orgynecomastia. Difference between two arms was statistically non-significant (p>0.05) except for dizziness which is significant (p<0.05) Table 4.

Discussion
The main objective of the study was to compare the left ventricular systolic function in chronic heart failure patients treated with spironolactone and eplerenone. In the present study, the baseline characteristics of the two treatment arms were same; therefore, the effectiveness of spironolactone and eplerenone is clearly comparable. The present study demonstrates that eplerenone improves cardiac performance to a greater extent than spironolactone during the 6 months treatment of patients with chronic heart failure. When compared with the spironolactonearm, the eplerenone group showed larger increases in LV ejection fraction and LV systolic dimension (volume and diameter) at rest. In contrast, no significant difference of improvement was observed in left ventricular diastolic dimension (LVIDd and LVEDV) and blood pressure between 2 arms. But the 2 drugs improved symptoms, exercise tolerance, and quality of life to a similar extent.

Swedberg et al., recommends aldosterone receptor antagonists in addition to ACE inhibitors, beta blockers and diuretics. Study reported that aldosterone antagonist spironolactone has been shown to improve survival in patients with chronic, severe heart failure. Eplerenone is a selective aldosterone antagonist expected to have a lower incidence of hormonal side effects than spironolactone. (Nadin et al., 2005)
In this study although no significant differences of adverse drug reactions were observed between arms, arm I or patients receiving spironolactone had experienced more adverse profile than eplerenone arm. Adverse profile of medication shows that, in arm I patients, gynecomastia occurred in 10.4% of patients, dizziness in 11.4%, mastalgia in 5.7%. In arm II patient’s dizziness occurred in 3.9% of patients, none of patients observed developed mastalgia, gynecomastia. The difference between the two arms was statistically non-significant except for dizziness which was significant.

Most previous studies that evaluate the hemodynamic response in 3 to 6 months of MRA therapy have reported benefits, including improvements in left ventricular ejection fraction and reduced ventricular volumes. Our findings are consistent with most of these studies, as measures of left ventricular end-diastolic volume, left ventricular end systolic volume, and ejection fraction tended to improve in both arms but more with eplerenone, although the reductions in end-diastolic volume did not reach statistical significance.

Our findings in accordance with result of other studies, which reported that in both arms, LVEF, improved significantly.

Reference
1. Bleumink, G.S., Knetsch, A.M., Sturkenboom, M.C.J.M., Straus, S.M.J.M., Hofman, A., Deckers, J.W. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. *European Heart Journal England*, 2004;25:1614–19.
2. Brunton, L., Hilal-Dandan, R., Knollmann, B. C. Goodman & Gilman the pharmacological basis of therapeutics. 13th ed. United States of America; McGraw-Hill Education. 2018; 534-35.
3. Butler, J., . Primary Prevention of Heart Failure. *International Scholarly Research Notices: Cardiology*, 2012:1-15.
4. Butler, J., Fonarow, G.C., Zile, M.R., Lam, C.S., Roessig, L., Schelbert, E.B. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. *Journal of American College of Cardiology: Heart Failure*, 2014;2:97-112.
5. Ceia, F., Fonseca, C., Mota, T., Morais, H., Matias, F., Sousa, A.D. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. *European Journal of Heart Failure*, 2002;4:531–39.
6. De Gasparo, M., Joss, U., Ramjoue, H.P., Whitebread, S.E., Haenni, H., Schenkel, L., Krachenbuehl, C., Biolaz, M., Grob, J., Schmidlin, J. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. *Journal of Pharmacology and Experimental Therapeutics*, 1987;240:650–56.
7. DiNicolantonio, J., Lavie, C., Fares, H., Menezes, A., James, H. Meta-Analysis of Carvedilol versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol). *American Journal of Cardiology*, 2013;111:765-69.
8. Drazner, M.H., Rame, J.E., Dries, D.L. Third heart sound and elevated jugular venous pressure as markers of the subsequent development of heart failure in patients with asymptomatic left ventricular dysfunction. *American Journal of Medicine*, 2003;114:431-37.
9. Drazner, M.H., Rame, J.E., Stevenson, L.W. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. *New England Journal of Medicine*, 2001;345:574–81.
10. Hall, J. Guyton and Hall textbook of medical physiology.13th ed. United States of America; Elsevier. 2016;115.
11. Hunt, S.A., Baker, D.W., Chin, M.H. American College of Cardiology / American Heart Association guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. *Journal of American College of Cardiology*, 2001;38:2101–03.
12. Institute for Clinical Systems Improvement (ICSI). 2004. Heart failure in adults. *Institute for Clinical Systems Improvement, USA*.
13. Available at: http://www.guideline.gov/summary/summary.aspx? [Accessed on 26th February 2018].
14. Iqbal, J., Parviz, Y., Pitt, B., Newell Price, J., Al Mohammad, A., Zannad, F. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. *European Journal of Heart Failure*, 2013;16:13-19.
15. Kirkwood, R.B., Sterne, A.C J. ‘Calculation of required sample size.’, in *Essential Medical Statistics*, 2nd Edition, 2006; 413-28.
16. Maggioni, A.P., Dahlstrom, U., Filippatos, G., Chioncel, O., Leiro, M.C., Drozdz. European Observational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). *European Journal of Heart Failure*, 2013;15:808–17.
17. Marrs, J., Anderson, S., Gabriel. Role of Aldosterone Receptor Antagonists in Heart Failure with Preserved Ejection Fraction. *Clinical Medicine Insights: Therapeutics*, 2018;10:1-4.
18. McKeilv, R., Yusuf, S., Pericak, D., Avezum, A., Burns, R., Probstfield, J., Tsuyuki, R., White, M., Rouleau, J., Latini, R., Maggioni, A., Young, J., Pogue, J. Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RESOLVD Pilot Study Investigators. *Circulation*, 1999;100:1056-64.
19. McMurray, J.J.V., Adamopoulos, S., Anker, S.D., Auricchio, A., Bohm, M., Dickstein, K. European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. *European Journal of Heart Failure*, 2012;14, 803–69.
20. Juurlink, D., Mamdani, M., Lee, D. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study (RALES). American College of Cardiology Current Journal Review, 2004;13:27.

21. Miller, A. Aldosterone antagonism in heart failure. Vascular Health Risk Management, 2007;3:605–09.

22. Mosterd, A., Hoes, A.W. Clinical epidemiology of heart failure. Heart, 2009;93:1137–46.

23. Nadin, C. Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction. Core Evidence, 2005;1:125–41.

24. Overdiek, H., Merkus, F. The Metabolism and Biopharmaceutics of Spironolactone in Man. Drug Metabolism and Drug Interactions, 1987;5:273-302.

25. Pitt, B., Pfeffer, M.A., Assmann, S.F. Spironolactone for heart failure with preserved ejection fraction (TOPCAT). New England Journal of Medicine, 2014;370:1383–92.

26. Ponikowski, P., Voors, A., Anker, S., Bueno, H., Cleland, J., Coats, A., 2016. European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). European Heart Journal, 2016;37: 2129–2200.

27. Sindone, A. Chronic heart failure: Improving life with modern therapies. Australian Family Physician, 2010;39:898-901.

28. Struthers, A., Krum, H., Williams, G.H. A comparison of the aldosterone-blocking agents: eplerenone and spironolactone. Clinical Cardiology, 2008;31:153–58.

29. Swedberg, K., Cleland, J., Dargie, H. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). European Heart Journal, 2005;26:1115–140.

30. The CONSENSUS Trial Study Arm. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine, 1987;316:1429–35.

31. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. Studies of Left Ventricular Dysfunction (SOLVD) trial. New England Journal of Medicine, 1992;327:685–91.

32. Udelson, J., Feldman, A., Greenberg, B., Pitt, B., Mukherjee, R., Solomon, H. and Konstam, M. Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Effect of Aldosterone Antagonism With Eplerenone on Ventricular Remodeling in Patients With Mild-to-Moderate Heart Failure and Left Ventricular Systolic Dysfunction. Circulation: Heart Failure, 2010;3:347-53.